Recent Updates
Recently added Catalysts
NKTX Positive Sentiment Score: 65/100

Nkarta to Participate in a September Investor Conference

Tuesday, September 2, 2025 1 min read
Key Takeaway: Nkarta, Inc. announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference, scheduled for September 2025. The company will present a fireside chat, accessible via a live webcast and archived on their website for 90 days. Nkarta focuses on developing engineered natural killer (NK) cell therapies aimed at treating autoimmune diseases, utilizing advanced cell engineering technologies. This event highlights the company's progress and commitment to innovation in biopharmaceuticals.

Market Sentiment Analysis

POSITIVE FACTORS

  • Nkarta is participating in a reputable investor conference, indicating confidence and interest in their progress.
  • The company is advancing innovative NK cell therapies, which could be significant for autoimmune disease treatment.

Full Press Release Details

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conference:
H.C. Wainwright 27th Annual Global Investment Conference
8:30 a.m. ET – fireside chat
A simultaneous webcast of the event will be available on the Investors section of Nkarta’s website, www.nkartatx.com, and a replay will be archived on the website for approximately 90 days.
Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for autoimmune diseases. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies and CRISPR-based genome engineering capabilities, Nkarta is building a pipeline of future cell therapies engineered for deep therapeutic activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company’s website at www.nkartatx.com.
Nkarta Media/Investor Contact:
nmahmood@nkartatx.com

Frequently Asked Questions

What is Nkarta, Inc. known for?

Nkarta, Inc. specializes in developing engineered natural killer cell therapies.

When is the H.C. Wainwright conference taking place?

The H.C. Wainwright 27th Annual Global Investment Conference is on September 2, 2025.

Where can I watch the Nkarta conference webcast?

The webcast will be available on Nkarta’s Investors section of their website.

What technology does Nkarta utilize for cell therapies?

Nkarta uses a combination of cell expansion, cryopreservation, and CRISPR-based engineering.

How long will the conference replay be available?

The replay of the event will be archived for approximately 90 days.

Tags: NKTX Viatris Investor Conferences Healthcare Nkarta NK cell therapies autoimmune diseases H.C. Wainwright biopharmaceuticals
Last updated: Sep 2, 2025